Two Unrelated Undervirilized 46,XY Males with Inherited *NR5A1* Variants Identified by Whole-Exome Sequencing

Jonathan M. Swartz^a Ryan Ciarlo^a Michael H. Guo^a Aser Abrha^a
David A. Diamond^b Yee-Ming Chan^a Joel N. Hirschhorn^a

^aDivision of Endocrinology and ^bDepartment of Urology, Boston Children's Hospital, Boston, Mass., USA

Established Facts

- Whole-exome sequencing has been used effectively in severe cases of disorders of sex development to yield a diagnosis.
- Heterozygous mutations in *NR5A1* have been identified as a cause of undervirilization in 46,XY males without adrenal insufficiency.
- The vast majority of inherited *NR5A1* cases reported in the literature in 46,XY males are from carrier mothers.

Novel Insights

- Whole-exome sequencing performed on ten 46,XY subjects with bifid scrotum led to the identification of potentially pathogenic heterozygous *NR5A1* mutations in 2 cases.
- One of the heterozygous *NR5A1* variants was inherited from an unaffected father, expanding the phenotypic spectrum associated with *NR5A1* variants reported in the literature.

Key Words

NR5A1 · Disorders of sex development · Bifid scrotum · Undervirilization · Exome sequencing

Abstract

Background: Undervirilized 46,XY males with bifid scrotum often pose a diagnostic challenge, and the majority of cases typically do not receive a genetic diagnosis. *NR5A1* mutations can be seen in 10–20% of the cases and are a relatively common cause of undervirilization. **Methods:** Whole-exome

sequencing was utilized to study 10 undervirilized 46,XY subjects with bifid scrotum. **Results:** Exome sequencing identified novel *NR5A1* variants, both affecting exon 7, in 2 of the 10 subjects with bifid scrotum. Subject 1 had a heterozygous frameshift variant, c.1150delC, p.Leu384fsTer1, within the ligand-binding domain inherited from his unaffected father. Subject 2 had a novel splice-site variant c.1139–2T>C, affecting the canonical splice acceptor site for exon 7 and also disrupting the ligand-binding domain. Both subjects had serum testosterone levels within the normal range as infants. **Conclusions:** We describe two novel *NR5A1* variants,

demonstrating mutations in this gene as a common cause of milder cases of 46,XY undervirilization. Whole-exome sequencing results yielded the diagnosis in 2 out of 10 cases without a previous diagnosis, supporting the value of this approach. Significant genotype-phenotype variability was also noted with Subject 1's paternal inheritance from his unaffected father.

© 2016 S. Karger AG, Basel

Introduction

Undervirilized 46,XY males are a challenging group of patients to evaluate, particularly when searching for an underlying genetic diagnosis. The broad phenotype can range from female-appearing external genitalia with or without mild clitoromegaly, to ambiguous genitalia, to typical male-appearing genitalia with hypospadias. While the more severe cases are readily recognized as disorders of sex development (DSD) [1], milder cases of hypospadias and bifid scrotum may not lead to a DSD label. Studies of exome sequencing applied to 46,XY DSD cases with frankly ambiguous genitalia has demonstrated the success of this approach in establishing a diagnosis in nearly one third of the cases, potentially avoiding expensive and extensive diagnostic odysseys [2]. It remains unclear if this diagnostic yield extends to milder cases.

This study applied whole-exome sequencing to 46,XY males with mild/moderate undervirilization, a group not previously assessed using exome sequencing. We selected 46,XY subjects with bifid scrotum as a narrowly defined phenotype who undergo varying degrees of evaluation and often do not receive genetic diagnoses. The majority of subjects with bifid scrotum were also noted to have hypospadias. For many, the phenotype is sufficiently mild that they do not receive a formal DSD workup; indeed, 40% are seen solely by surgeons in the setting of hypospadias repair and undergo few if any diagnostic tests [Swartz et al., in preparation]. The initial clinical workup for these patients can vary but may involve ruling out congenital adrenal hyperplasia (such as 21-hydroxylase deficiency or 3 β -hydroxysteroid dehydrogenase deficiency), performing ultrasound imaging, obtaining a karyotype, and ordering targeted genetic testing [3]. Partial androgen insensitivity with an androgen receptor (*AR*) mutation is one of the most frequently identified genetic causes of undervirilization [4]. Mutations in *NR5A1*, the gene-encoding steroidogenic factor-1 (SF-1), is another cause of undervirilization, seen in as many as 10–20% of all cases of undervirilization [5, 6]. The phenotypic spectrum of

disease with *NR5A1* is quite variable. Early reports of biallelic *NR5A1* mutations were found in patients with complete gonadal dysgenesis and adrenal failure [7–9]. In recent years, there have been a number of publications focused on the wide phenotypic spectrum associated with monoallelic (heterozygous) *NR5A1* mutations, including cases of undervirilization without adrenal insufficiency [10–12]. The relatively common 46,XY undervirilized phenotype associated with testicular dysgenesis in the setting of heterozygous *NR5A1* mutations appears to be much more common than the rare homozygous cases with associated adrenal insufficiency [5].

This study addresses the diagnostic yield of whole-exome sequencing in a cohort of 10 subjects with bifid scrotum. To our knowledge, this is the first study to apply systematic exome-wide evaluation of mild-to-moderate undervirilization to better understand the underlying molecular genetics. The findings also have the potential to yield insights into whether these cases share a genetic etiology with more classical DSD presentations.

Methods and Subjects

Subjects and Clinical History

This study was approved by the Boston Children's Hospital Institutional Review Board. All subjects provided written informed consent and assent (when appropriate). All probands were known to have a 46,XY karyotype and no identified genetic etiology. The majority of cases had physical findings of bifid scrotum with proximal hypospadias, consistent with mild-to-moderate undervirilization. Presence and location of testes and penile measurements were extracted from medical records. These individuals were all assigned a male gender at birth and had evaluations of hormonal and gonadal function to varying extents depending on clinical providers.

Subject 1 was born at 39.1 weeks of gestation by Cesarean section and shortly after delivery was noted to have bifid scrotum, penoscrotal hypospadias, and chordee. The parents were expecting a female infant based on prenatal imaging. Both testes were palpable in prominent, rugated labioscrotal folds. His stretched phallic length was 2.4 cm, and his midshaft diameter was 1.1 cm. Family history was unremarkable, and the parents were not consanguineous. An ultrasound confirmed the presence of inguinal testes bilaterally and revealed absence of Müllerian structures. Laboratory assessment for adrenal steroid biosynthetic defects due to 3 β -hydroxysteroid dehydrogenase deficiency, 17 α -hydroxylase deficiency and 17,20 desmolase deficiency ruled out these conditions. He was found to have a 46,XY karyotype, supporting a male gender assignment. His first testosterone measurement on day of life 3 was 21 ng/dl. Levels were remeasured in the setting of a human chorionic gonadotropin (hCG) stimulation test at approximately 1 month of age. His baseline and stimulated testosterone levels were 195 ng/dl (reference 233 $\pm$ 88) and 349 ng/dl, respectively, and his dihydrotestosterone (DHT) levels were 193 pg/ml (reference 50–600) and 415 pg/ml. He also had a cortisol level of

Fig. 1. NR5A1 gene structure with location of heterozygous mutations in Subjects 1 and 2. Both mutations involved exon 7 in the ligand-binding domain [adapted from 6 and 19]. AF-2 = Activation function domain 2; Ftz-F1 = fushi tarazu factor 1 box. Figure not according to scale.

18.6 µg/dl and an ACTH level of 30 pg/ml (reference <45) included in his post-hCG results. These results were interpreted as demonstrating robust testicular function and normal conversion of testosterone to DHT. This supported the presumed male gender assignment. Subject 1 also had AR sequencing completed in the course of his clinical care, and this testing did not show any pathogenic variants. He was followed until the age of 2 without any additional testing. He underwent urologic surgery to repair his hypospadias during this time. At the age of age 2, his penis remained small, and his clinical providers treated him with testosterone enanthate 50 mg i.m. monthly ×3 doses. This resulted in an increased stretched penile length from 3.2 to 4.6 cm, and his midshaft diameter increased from 1.6 to 2.1 cm, demonstrating a robust response to testosterone. He was otherwise developmentally appropriate for his age.

Subject 2 was born at 40.9 weeks of gestation by vaginal delivery and was also noted to have bifid scrotum, penoscrotal hypospadias, and bilateral 1-ml scrotal gonads. Prenatal ultrasounds had suggested the baby appeared female. His scrotum was rugated and pigmented. His stretched phallic length was 2 cm, and his midshaft diameter was 1 cm. He had incomplete scrotal fusion and an anogenital ratio of 0.75. Family history was without any fertility issues or genitourinary abnormalities. The mother of the proband still has regular menses at the age of 33. The maternal grandmother had hot flashes, headaches, and sleep issues starting at the age of 39. Menses stopped by the age of 44. An ultrasound showed normal-appearing scrotal testes with a blind-ending vaginal pouch and no Müllerian structures. He had an evaluation of adrenal hormones and precursors that ruled out 17β-hydroxysteroid dehydrogenase deficiency, 17,20-lyase deficiency and 3β-HSD deficiency. His karyotype returned as 46,XY. He had a serum testosterone level of 48 ng/dl on day of life 1 and a stimulated cortisol level of 26.8 µg/dl at 2 weeks, indicating normal adrenal function. At the age of 3 weeks, luteinizing hormone was 8.93 IU/l, follicle-stimulating hormone was 7.97 IU/l, testosterone was 177 ng/dl and DHT was 301 pg/ml. Following 3 days of hCG stimulation, his testosterone rose to 231 ng/dl and DHT to 500 pg/ml, consistent with appropriate testicular function. By 1 month of age, his penis size increased without treatment to a stretched length of 2.5 cm with a midshaft

diameter of 1 cm. This improvement was thought to be related to his endogenous testosterone and, given the appropriate dimensions for age, he did not receive exogenous i.m. testosterone nor was it recommended that he have AR sequencing.

Genetic Analyses

Whole-exome sequencing of blood or saliva-derived genomic DNA was performed at the Broad Institute (Cambridge, Mass., USA) on 10 probands as well as parents from 6 of the probands. For hybrid selection, we used the custom Illumina Content Exome capture kit (Illumina, San Diego, Calif., USA). Sequencing reads were aligned to the hg19 reference genome [13]. We applied the Genome Analysis Toolkit (GATK) for base quality score recalibration and indel (insertion-deletion) realignment [14]. Variant quality score recalibration was simultaneously performed for single-nucleotide polymerase (SNP) and indel discovery according to GATK Best Practices recommendations [15, 16]. We used SnpEff (<http://snpeff.sourceforge.net/>) for functional annotation. We filtered for variants that were novel or found in less than 1% of the reference population based on allele frequencies from the Exome Aggregation Consortium (ExAC; <http://exac.broadinstitute.org/>) [17]. Based on the quality standards at the Broad Institute, at least 80% of the exome had ×20 coverage. When parental sequencing was performed, we additionally filtered for de novo variants that were absent in ExAC. Results were reviewed for variants in known DSD-related genes previously reported [2] as well as for genes near hypospadias loci identified by a genome-wide association study [18]. Sanger sequencing was performed to confirm the variants of interest along with sex-determining region of Y confirmation when indicated.

Hormonal Assays

Luteinizing hormone and follicle-stimulating hormone were analyzed on the Roche e170 analyzer (Roche Diagnostics, Indianapolis, Ind., USA) using a chemiluminescent immunoassay. Testosterone and DHT were measured by quantitative liquid chromatography/tandem mass spectrometry at Boston Children's Hospital (Boston, Mass., USA) and ARUP Laboratories (Salt Lake City, Utah, USA), respectively.

Table 1. Clinical characteristics and laboratory measurements for the 10 subjects with bifid scrotum

ID	GA	Clinic visit	Phallic stretched length ^a , cm	Phallic midshaft diameter ^a , cm	Hypospadia degree	Gonadal location	Testosterone ^b , ng/dl	DHT ^b , pg/ml	LH ^b , IU/l	FSH ^b , IU/l	Clinical AR sequencing	Non-GU abnormalities
1 ^c	39.1	both	2.1	0.9	penoscrotal	scrotal	195	193	4.34	NR	yes, no diagnosis	none
2 ^c	40.9	both	2	1	perineal	scrotal	177	301	8.93	7.97	no	none
3	40.0	urology	NR	NR	no hypospadias	scrotal	NR	NR	NR	NR	no	tethered cord, anteriorly placed anus, renal abnormalities
4	33.0	both	2.5	1.1	penoscrotal	scrotal	132	462	3	3.34	no	intrauterine growth restriction
5	41.0	both	3.2	1.1	perineal	inguinal	NR	NR	NR	NR	no	none
6	34.7	both	NR	NR	scrotal	scrotal	207	71	NR	NR	yes, no diagnosis	none
7	37.0	both	NR	NR	scrotal	scrotal	NR	NR	NR	NR	no	global developmental delay
8	35.3	urology	NR	NR	penoscrotal	scrotal	NR	NR	NR	NR	no	none
9	39.1	urology	NR	NR	glanular	scrotal	NR	NR	NR	NR	no	ventricular septal defect
10	39.0	both	2	1.1	perineal	scrotal	85.9	29	5.23	4.62	no	none

GA = Gestational age in weeks; GU = genitourinary; NR = not reported. Clinic visit: Department of Urology or both Division of Endocrinology and Department of Urology [at any point in the electronic medical record (EMR)]. Testosterone: ng/dl $\times$ 0.03467 = nmol/l. DHT: pg/ml $\times$ 0.003443 = nmol/l. ^a Initial measurement reported between birth and 3 months of age. ^b Baseline measurement between 2 weeks and 3 months. ^c Subjects found to have presumed pathogenic variants of *NR5A1*.

Results

The clinical characteristics and laboratory measurements for the 10 subjects with bifid scrotum who had exome sequencing performed are detailed in table 1. Most subjects had severe hypospadias in addition to bifid scrotum. Laboratory measurements during the first few months of life, when the gonadotropin axis is active, were available for half of the subjects.

Exome sequencing identified 2 subjects with presumed pathogenic mutations in known DSD-associated genes – both in *NR5A1* (fig. 1) [6, 19], which had not been sequenced as part of the clinical evaluation in any of the 10 subjects. Subject 1 was found to have a heterozygous frameshift variant, c.1150delC, p.Leu384fsTer1, within the ligand-binding domain. This frameshift variant is predicted to result in premature cessation of translation, with nearly 80 fewer amino acids than the wild-type protein product. This variant was not present in any of the 60,706 exomes in ExAC. A nearly identical frameshift variant, c.1151del, p.Leu384Argfs*7, was recently reported in a 46,XY female with clitoromegaly and was shown to have significantly decreased activity of the protein product SF-1 on functional assays [20]. Sequencing of Subject 1's parents revealed the same variant in the subject's father. The presence of the sex-determining region

of Y was confirmed in Subject 1's father to ensure that parental samples were not switched. Evaluation of the father's exome-sequencing results did not show any evidence of somatic mosaicism – the frameshift variant was found in 8 of 11 sequence reads. The father denied any history of genital abnormalities, known hormonal abnormalities, or surgeries.

Subject 2 was found to have a heterozygous novel splice-site variant, c.1139–2T>C. The variant disrupts a canonical splice acceptor site and is predicted to perturb the normal splicing of exon 7, which encodes a portion of the ligand binding domain of SF-1. Subject 2's mother was found to have the same *NR5A1* variant. As shown in table 1, there were no obvious clinical differences between the subjects found to have *NR5A1* variants as compared to the rest of the cohort.

No other pathogenic or likely pathogenic variants in known DSD genes [2], including *AR*, were identified in the cohort of 10 subjects.

Discussion

Establishing genetic diagnoses in individuals with undervirilization has the potential to improve the care of these patients. As next-generation-sequencing costs con-

tinue to decrease, more comprehensive sequencing approaches have already started to supplant targeted single-gene testing. Prior exome-based studies have focused on classic DSD cases with ambiguous genitalia [2]. To our knowledge, this study is the first to apply whole-exome sequencing to a cohort of cases with bifid scrotum and hypospadias but not frank genital ambiguity.

In our study of bifid scrotum cases, 2 of the 10 patients were found to have *NR5A1* variants that are likely to be pathogenic. This finding is consistent with previous reports that found pathogenic *NR5A1* variants in 10–20% of the DSD cases with varying degrees of undervirilization without adrenal insufficiency [5]. In a related chart review, we found that *AR* mutations were identified in 2 of 10 patients with bifid scrotum during standard clinical evaluation [Swartz et al., in preparation]. Thus, either whole-exome sequencing or targeted sequencing of *AR* and *NR5A1* may provide a diagnosis in a significant proportion of 46,XY cases with bifid scrotum. This information can guide the understanding of recurrence risk in a family and help inform expected progression of symptoms, appropriate dose of hormonal supplementation (if needed), tumor risk, and fertility.

A number of *NR5A1* mutations have been previously described in the literature. Heterozygous or homozygous *NR5A1* mutations can cause DSD, and its gene product SF-1 plays a role in both gonadal and adrenal development as well as steroidogenesis. SF-1 is an orphan nuclear receptor with a central role as a transcription factor for the regulation of adrenal and gonadal developmental genes including *SOX9*, *NR0B1*, and *AMH* as well as many genes encoding enzymes essential for steroid hormone synthesis [21]. Previous reports have noted that the degree of undervirilization appears greater than the degree of testicular dysgenesis in many of the described cases [21].

The observation of paternal inheritance of the *NR5A1* mutation in Subject 1 is an unusual finding from this study. To date, the vast majority of familial *NR5A1* mutations have been inherited maternally [22, 23], as in the case of Subject 2. There is one report of a missense *NR5A1* variant inherited from an unaffected father with normal external genitalia and maintained fertility, but in that case the father was believed to have low-level somatic mosaicism [22]. There are also reports of paternal inheritance of frameshift variants from affected fathers with hypospadias but intact fertility [24], as well as reports of an extended family with an *NR5A1* missense variant transmitted via an affected male with hypospadias [25]. Our finding of a frameshift variant inherited from Subject 1's apparently unaffected father is very unusual in the *NR5A1*

literature, especially given the lack of evidence of somatic mosaicism on sequencing results. This may be an example of the incomplete penetrance in *NR5A1* cases. Alternatively, digenic inheritance is a possibility with an additional yet to be identified gene influencing the phenotypes of different family members. Monoallelic expression is also a potential factor, though enough cases have been reported in the literature that this pattern would potentially have been identified already. It is also possible that Subject 1's father has a mild phenotype with some degree of endocrine dysfunction and/or subclinical oligospermia. The splice site variant in Subject 2 is also relatively uncommon in the *NR5A1* literature, with only a few reports of splice site variants in *NR5A1* published to date [12, 26].

This study highlights that normal testosterone levels during infancy, either at baseline or after hCG stimulation, do not rule out *NR5A1* mutations. Most prior reports found low levels of testosterone in undervirilized *NR5A1* cases, though there have been some reports of normal androgen biosynthesis in such patients [6, 11, 12, 24, 27]. The evidence of undervirilization at birth indicates decreased androgen signaling during early fetal development, but this signaling abnormality may not be evident on later testing. This raises a yet unanswered question about the role of SF-1 in steroidogenesis during early fetal life compared to postnatal life. This may be an indication that intra-individual variability on the impact of SF-1 variants on steroidogenesis at different developmental times (e.g., in utero vs. postnatal life) may be as relevant as inter-individual variability seen within families with the same *NR5A1* variants [23].

This study also demonstrates the utility of genetic testing in patients with bifid scrotum and hypospadias. Exome sequencing was shown to be high yield in more severe DSD cases, with a likely genetic diagnosis being identified in about one third of the patients with 46,XY DSD [2]. Our study suggests that exome sequencing is similarly high yield in milder cases of undervirilization. There is evidence that a significant fraction of bifid scrotum cases may have an identifiable genetic mutation that will improve disease understanding as well as be important for families interested in having additional children. These findings have significant implications for families and their management in the clinical setting. The recommendations for testing have been evolving in recent years with the decreasing costs of whole-exome sequencing. Although targeted single-gene testing is reasonable when there is a high pre-test probability of a pathogenic result, the cost of multiple single-gene Sanger sequencing quickly outpaces the cost of next-generation-sequencing approaches (either

disease-specific panel or whole exome) [28]. This will be a more and more significant consideration as the costs of next-generation sequencing continue to decline. Even with these factors to consider, challenges remain significant given the difficulty in obtaining insurance coverage for clinical whole-exome sequencing. Based on our findings, we feel it is reasonable to perform a genetic evaluation for all children with bifid scrotum and hypospadias, even those with a normal hormonal profile, as the genetic evaluation is reasonably likely to establish a diagnosis, which in turn can guide counseling about the risk for future siblings, treatment, and prognosis.

Acknowledgements

We are grateful to all patients and families willing to participate in this study – for their time and contributions in helping to advance the field. We also thank Dr. Christina Astley and Ms. Kara McLaughlin for their advice and assistance in completing this

study. We would finally like to thank the ExAC and the groups that provided exome variant data for comparison. A full list of the contributing groups can be found at <http://exac.broadinstitute.org/about>. This work was supported by National Institutes of Health (NIH) Grant 5T32DK007699-32 (J.M.S.), the March of Dimes Foundation, as well as the Manton Center for Orphan Disease Research. This work was also conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.

Disclosure Statement

The authors have no relevant conflicts of interest to disclose.

References

- Hughes I, Houk C, Ahmed SF, Lee P, Lawson Wilkins Pediatric Endocrine Society/European Society for Paediatric Endocrinology Consensus Group: Consensus statement on management of intersex disorders. *J Pediatr Urol* 2006;2:148–162.
- Baxter RM, Arboleda V, Lee H, Barseghyan H, Adam MP, Fechner PY, et al: Exome sequencing for the diagnosis of 46,XY disorders of sex development. *J Clin Endocrinol Metab* 2015;100:E333–E344.
- Arboleda V, Lee H, Sánchez FJ, Délot EC, Sandberg DE, Grody WW, et al: Targeted massively parallel sequencing provides comprehensive genetic diagnosis for patients with disorders of sex development. *Clin Genet* 2013;83:35–43.
- Ahmed SF, Bashamboo A, Lucas-Herald A, McElreavey K: Understanding the genetic aetiology in patients with XY DSD. *Br Med Bull* 2013;106:67–89.
- Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC: DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. *Best Pract Res Clin Endocrinol Metab* 2015;29:607–619.
- Camats N, Pandey AV, Fernández-Cancio M, Andaluz P, Janner M, Torán N, et al: Ten novel mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals. *J Clin Endocrinol Metab* 2012;97:E1294–E1306.
- Achermann JC, Ito M, Hindmarsh PC, Jameson JL: A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. *Nat Genet* 1999;22:125–126.
- Ito M, Achermann JC, Jameson JL: A naturally occurring steroidogenic factor-1 mutation exhibits differential binding and activation of target genes. *J Biol Chem* 2000;275:31708–31714.
- Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, et al: Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. *J Clin Endocrinol Metab* 2002;87:1829–1833.
- Lin L, Philibert P, Ferraz-de-Souza B, Kelberman D, Homfray T, Albanese A, et al: Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function. *J Clin Endocrinol Metab* 2007;92:991–999.
- Köhler B, Lin L, Ferraz-de-Souza B, Wieacker P, Heidemann P, Schröder V, et al: Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. *Hum Mutat* 2008;29:59–64.
- Köhler B, Lin L, Mazon I, Cetindag C, Biebermann H, Akkurt I, et al: The spectrum of phenotypes associated with mutations in steroidogenic factor 1 (SF-1, NR5A1, Ad4BP) includes severe penoscrotal hypospadias in 46,XY males without adrenal insufficiency. *Eur J Endocrinol* 2009;161:237–242.
- Li H, Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754–1760.
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, et al: The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297–1303.
- DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al: A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 2011;43:491–498.
- Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al: From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* 2013;43:11.10.1–33.
- Lek M, Karczewski K, Minikel E, Samocha K, Banks E, Fennell T, et al: Analysis of protein-coding genetic variation in 60,706 humans. *bioRxiv* 2015. <http://biorxiv.org/content/early/2015/10/30/030338.abstract>.
- Geller F, Feenstra B, Carstensen L, Pers TH, van Rooij IA, Körberg IB, et al: Genome-wide association analyses identify variants in developmental genes associated with hypospadias. *Nat Genet* 2014;46:957–963.
- Wong M, Ramayya MS, Chrousos GP, Driggers PH, Parker KL: Cloning and sequence analysis of the human gene encoding steroidogenic factor 1. *J Mol Endocrinol* 1996;17:139–147.

- 20 Woo KH, Cheon B, Kim JH, Cho J, Kim GH, Yoo HW, et al: Novel heterozygous mutations of NR5A1 and their functional characteristics in patients with 46,XY disorders of sex development without adrenal insufficiency. *Horm Res Paediatr* 2015;84:116–123.
- 21 Lin L, Achermann JC: Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development. *Sex Dev* 2008;2:200–209.
- 22 Philibert P, Polak M, Colmenares A, Lortat-Jacob S, Audran F, Poulat F, et al: Predominant Sertoli cell deficiency in a 46,XY disorders of sex development patient with a new NR5A1/SF-1 mutation transmitted by his unaffected father. *Fertil Steril* 2011;95:5–9.
- 23 Warman DM, Costanzo M, Marino R, Berensztejn E, Galeano J, Ramirez PC, et al: Three new SF-1 (NR5A1) gene mutations in two unrelated families with multiple affected members: within-family variability in 46,XY subjects and low ovarian reserve in fertile 46,XX subjects. *Horm Res Paediatr* 2011;75:70–77.
- 24 Baetens D, Mladenov W, Delle Chiaie B, Menten B, Desloovere A, Iotova V, et al: Extensive clinical, hormonal and genetic screening in a large consecutive series of 46,XY neonates and infants with atypical sexual development. *Orphanet J Rare Dis* 2014;9:209.
- 25 Ciaccio M, Costanzo M, Guercio G, De Dona V, Marino R, Ramirez PC, et al: Preserved fertility in a patient with a 46,XY disorder of sex development due to a new heterozygous mutation in the NR5A1/SF-1 gene: evidence of 46,XY and 46,XX gonadal dysgenesis phenotype variability in multiple members of an affected kindred. *Horm Res Paediatr* 2012;78:119–126.
- 26 Takagi M, Nishina N, Yagi H, Hasegawa Y: Functional characterization of c.870 + 3_6del-GAGT splice site mutation in NR5A1. *Horm Res Paediatr* 2016;85:65–68.
- 27 Wu JY, McGown IN, Lin L, Achermann JC, Harris M, Cowley DM, et al: A novel NR5A1 variant in an infant with elevated testosterone from an Australasian cohort of 46,XY patients with disorders of sex development. *Clin Endocrinol (Oxf)* 2013;78:545–550.
- 28 Achermann JC, Domenice S, Bachega TA, Nishi MY, Mendonca BB: Disorders of sex development: effect of molecular diagnostics. *Nat Rev Endocrinol* 2015;11:478–488.